Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Directory
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Soligenix
Sort By
Newest First
1 / 1
Soligenix, Inc.
Clinical CRO
HyBryte™ Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
Soligenix, Inc.
PR-01-25-NI-10
Jan 14, 2025
Soligenix, Inc.
Clinical Trials
Soligenix Announces Partnership with Sterling Pharma Solutions
Soligenix, Inc.
PR-09-24-NI-32
Oct 07, 2024
Soligenix, Inc.
Clinical Trials
HyBryte™ expanded treatment results to be presented at the European Organisation for research and treatment of cancer conference
Soligenix, Inc.
PR-10-24-NI-33
Oct 07, 2024
Phase III
Soligenix Announces Phase 3 FLASH Study Continues to Demonstrate Positive Benefits in Patients with Cutaneous T-Cell Lymphoma
PR-M10-20-14
Oct 22, 2020
Soligenix, Inc.
Fast Track
FDA Grants Soligenix "Fast Track" Designation for RiVax® in the Prevention of Ricin Poisoning
Soligenix, Inc.
PR-M02-20-NI-019
Feb 14, 2020
Soligenix, Inc.
Clinical Trials
Soligenix Announces Positive Recommendation on its Phase 3 Clinical Trial for the Treatment of Oral Mucositis
Soligenix, Inc.
PR-M09-19-NI-007
Sep 04, 2019
Soligenix, Inc.
Vaccine
Soligenix Announces Publication Demonstrating Thermostabilization of an Ebola Subunit Vaccine Candidate
Soligenix, Inc.
PR-M02-19-NI-023
Feb 11, 2019
Soligenix, Inc.
Phase 3
Soligenix Announces Positive Recommendation by Independent Data Monitoring Committee on its Phase 3 Clinical Trial of SGX301
Soligenix, Inc.
PR-M10-18-NI-054
Oct 16, 2018
1 / 1
